According to Yale University scientists, this new novel treatment option was crafted as a way to treat alopecia universalis - a disease that leaves its victims almost entirely bare of hair. The university reports that the results of experimental testing on a 25-year-old male patient mark the first successful targeted treatment of this disease in medical history. King is the senior author of a study published in the Journal of Investigative Dermatology that details this success. According to the study, the male study participant was placed on a daily regimen of 10 mg of tofacitinib citrate - a preexisting FDA-approved...